Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
Neo-Healer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
- NCT06747338 ↗
- Active, not recruiting
- Shanghai JMT-Bio Inc.
- Focused
We haven't built an HCP commentary report on Neo-Healer (anbenitamab plus HB1801 in early or locally advanced HER2-positive breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Neo-Healer so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Early or Locally Advanced HER2-positive Breast Cancer
- Interventions
- KN026; HB1801; Pertuzumab; Trastuzumab; Docetaxel; Carboplatin
- Arms
- KN026 plus HB1801 ± Carboplatin · Experimental
- Pertuzumab and trastuzumab plus docetaxel ± Carboplatin · Active comparator
- Enrollment
- 520 (estimated)
- Primary outcomes
- tpCR (BIRC, AJCC 8th)
- Sponsor
- Shanghai JMT-Bio Inc.
- Start
- Dec 16, 2024
- Primary completion
- Dec 16, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06747338 · updated Jul 7, 2026
Publications
linked from the registry- Li J, Liu T, Yu KD, Yang H, Huang Z, Zeng Y, Ji P, Hou X, Liu C, Zhang Y, Li N, Ouyang Z, Wu X, Bai X, Guo Y, Han G, Cui S, Zhu Z, Zhang Y, Hu X, Ma X, Fu P, Zhu J, Dong Y, Wu T, Jia H, Xu F, Ren Y, Nie J, Bing D, Mu Q, Sun T, Luo J, Song Z, Kong X, Zhang H, Wu Z, Wang Z, Song D, Jia H, Tao W, Fan P, Yao F, Ru C, Lai G, Zhou X, Li T, Deng C, Jiang X, Wang X, Wang J, Xiong D, Zhang S, Yang H, Yao Y, Yin G, Yao G, Zhou L, Wang S, Yu Z, Yu Y, Lv Y, Qian H, Li H, Guo W, Huang W, Xiang S, Zou K, He H, Fan L, Shao ZM; BCTOP study group. Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 3:e263329. doi: 10.1001/jamaoncol.2026.3329. Online ahead of print. PubMed 42690668